Board of Directors
Stephen C. Glover
Co-Founder, Chief Executive Officer, and Chairman
Mr. Glover has over 32 years of business experience in biopharmaceuticals and life sciences. Mr. Glover was formerly the Co-Founder of Coherus Biosciences where he was focused on business strategy, partnerships, product development efforts, and capitalization of the company. Prior to Coherus, he was the President of Insmed Therapeutic Proteins as well as Chief Business Officer of Insmed Incorporated. At Insmed, Mr. Glover was responsible for the creation of the biosimilar business unit and the divestiture of the business to Merck. As Chief Business Officer he led Insmed's strategic review process which resulted in the merger of Insmed and Transave. Prior to Insmed, Mr. Glover held the position of Senior Vice President and General Manager at Andrx Laboratories and Andrx Therapeutics, both divisions of Andrx Corporation. At Andrx Mr. Glover was responsible for the strategy and operation of the Andrx Labs which developed and marketed products in metabolic diseases and Men's Health, and Andrx Therapeutics which was focused on the development of new controlled release products and contract manufacturing. He earlier held multiple sales, marketing and operational roles at Hoffman LaRoche, Amgen Inc. and IMS Health. Mr. Glover has multifaceted experience in Fortune 100, start up and entrepreneurial environments. His transaction experience covers over 25 transactions totaling over $10 billion, and he serves on the Boards of PDS Biotechnology and Asclepius Lifesciences.
Jules A. Müsing
Former CEO & President of Janssen (Johnson & Johnson) companies and Ares-Serono, Inc.
In the course of his career in the Pharmaceutical and Biotechnology Industry, mainly at Johnson & Johnson [NYSE: JNJ], Jules A. Müsing has been responsible for the worldwide licensing and acquisition of pharmaceutical and biotechnology prescription products and technologies and the establishment of corporate strategic alliances.
In this position he negotiated, signed and implemented several multi-million dollar deals with small, medium and large Pharmaceutical and Biotechnology companies on a worldwide basis.
He has more than 40 years' experience in the pharmaceutical and biotechnology industry, and has been Chief Executive Officer, President and Managing Director of Johnson & Johnson companies in the US and in Europe and of the Swiss-based company Ares Serono in the US. He also has been Executive Vice President of all Ares Serono companies in North- and Latin America.
Additional accomplishments relate to his business development activities in S.E. Asia, where he was instrumental in the establishment of Johnson & Johnson pharmaceutical subsidiaries in Japan, Australia, South Africa, Thailand and other S.E. Asian countries, and to his role of Vice President Marketing International for the Janssen Group of Companies Worldwide.
Mr. Müsing currently serves as a member of the Board of Directors of TherapeuticsMD, Inc. and of Delphi Digital, Inc. He is also Chairman of the Scientific Advisory Board of Noble Capital Markets, an Investment Banking and Merchant Banking boutique in Boca Raton, Florida.
Mr. Müsing previously served as a member of the Board of Directors of Johnson & Johnson companies in Germany, France, Italy and the UK and served as a member of the Management Board of Ortho Biotech, a Johnson & Johnson biotechnology company in the US and in Europe. He also served as Executive Chairman of Pelican Therapeutics, Inc. and as a member of the Board of Directors of iBio, Inc.
Jules A. Müsing received his Postgraduate degree of Master in Sciences from the University of Brussels (Belgium) and his Academic degree in Economic and Financial Sciences - Cum Lauda - from the University of Antwerp (Belgium). He also completed several Postgraduate courses at Harvard University, US and the University of Cambridge, UK. His Honors thesis on the European Monetary Union (1975) was awarded with "special recognition" by the Prime Minister of Belgium.
He has been speaker and moderator at several national and international Healthcare conferences and congresses, and is an advisor to a number of Biotechnology and Pharmaceutical companies.
Robert (Rob) G. Finizio
Chief Executive Officer, Co-Founder, and Director of TherapeuticsMD Inc.
Mr. Finizio is Chief Executive Officer, Co-Founder, and Director of TherapeuticsMD Inc., an innovative women's health pharmaceutical company. With over 20 years of healthcare experience, Rob started his career in an operational role at Endoscopy Specialist, Inc. (ESI), a leader in laparoscopic equipment outsourcing and intraoperative technical support. During his tenure at ESI, Rob advanced to a regional management role, eventually leaving to join Omnicell Technologies (OMCL), a leader in pharmacy automation.
While at Omnicell, Rob served as a sales director, ultimately leaving the company to co-found CareFusion in 2001. CareFusion was a pioneer in hospital patient safety systems for Medication, Blood, and Specimen verification at the point of care. The company was successfully sold to Cardinal Health in 2006.
Rob co-founded TherapeuticsMD (TXMD) in 2008, combining his background in women's healthcare, pharmaceutical technology, clinical software, and patient safety. Today, TXMD is a leader in women's health, pharmaceutical development, and commercialization. In 2011, Rob took TXMD public, with a current market capitalization of over a billion dollars. Since inception, Rob raised more than $500 million in capital and listed TXMD on the NYSE before transferring to the Nasdaq in 2017.
Rob sits on the Board of Directors for two non-profit organizations, BioFlorida and the Boca Raton Police Foundation. Prior to his healthcare career, Rob, a University of Miami graduate who earned a Bachelor of Arts degree majoring in Premed and Psychology, taught English in Osaka, Japan.
Minchul Park, Ph.D
Chief Executive Officer, and Director of Curebio Therapeutics
Adjunct Professor, Korea University, Department of Pharmacy
Dr. Park is Chief Executive Officer, and Director of Curebio Therapeutics, a biopharmaceutical company in Seoul, Korea, which develops peptide drugs for cancer, alopecia, and wound care. With 10 years in the pharmaceutical industry, Dr. Park has worked in the field of drug target discovery, assay development, and drug candidate optimization. He has expertise in basic and applied molecular and cellular biology.
In his current role, Dr. Parks has led financing and business development deals, including co-development agreements with three pharmaceutical companies, one in-license deal, and he has raised $7 million in equity. Additionally, he has developed cosmetic peptides, and he co-developed antibodies, circulating tumor cell-based diagnostics, and a cancer stem cell assay system.
Prior to Curebio, Dr. Park was CEO and Director at Neomics in Seoul, Korea, where he led the company to profitability by expanding the contract experiment and biomaterial business, and he led efforts to merge Neomics with Curebio and Bumyoung Bio Co., Ltd to form Curebio. Dr. Park developed cosmetic peptides, and a dermatology peptide drug candidate that he out-licensed.
Dr. Park began his career as a Senior Research Associate at Medicinal Bioconvergence Research Center at Seoul National University, where he developed and led an out-licensing deal for an exosome isolation device, and he was responsible for two out-licensing deals for an anti-tumorigenic peptide.
Dr. Park obtained his PhD in pharmaceutical bioscience at the Seoul National University, Department of Pharmacy.